Clinical Trials

Endometrial Neoplasms

NCT04165772 2026-05-13

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

212 enrolled

Rectal Neoplasms

NCT04584255 2026-05-13

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

62 enrolled

Breast

Breast Neoplasms

NCT04774419 2026-05-13

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

62 enrolled

Endometrial Neoplasms

NCT04313504 2026-05-07

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Phase 2 Completed

10 enrolled 9 charts

Head and Neck Neoplasms

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06023862 2026-05-06

DOVE

198 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT07408063 2026-04-29

BeeHive

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04701307 2026-04-22

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

48 enrolled

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Phase 1/2 Recruiting

37 enrolled

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

NCT03680508 2026-04-02

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

42 enrolled

Phase 1 Active not recruiting

Carcinoma, Hepatocellular

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

10 enrolled

Dermatologic

Skin Neoplasms

NCT06830239 2026-02-12

Superhero

10 enrolled

Colonic Neoplasms

NCT04068753 2026-02-10

STAR

66 enrolled

Uterine Cervical Neoplasms

NCT05700721 2026-02-05

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Phase 2 Not yet recruiting

120 enrolled

CNS

Brain Neoplasms

NCT07381777 2026-02-02

IMMUNOSTAR

270 enrolled

Locally Advanced Rectal Cancer (LARC)

NCT07336147 2026-01-14

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma

45 enrolled

Uterine Cervical Neoplasms

NCT06238635 2026-01-13

Dostarlimab and Cobolimab in Advanced Cervical Cancer

66 enrolled

Phase 1 Active not recruiting

Uterine Cervical Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

18 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03955978 2026-01-06

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Phase 1 Active not recruiting

10 enrolled

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT03651206 2025-12-19

ROCSAN

Phase 2/3 Recruiting

138 enrolled

GynecologicSarcoma

Ovarian Carcinosarcoma

NCT05201547 2025-12-04

DOMENICA

260 enrolled

Neoplasm Metastasis, Endometrial Neoplasms

NCT05526989 2025-12-04

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

25 enrolled

Genitourinary

Penile Neoplasms

NCT06333314 2025-12-02

Pan-MSI-ACSE

GastrointestinalGenitourinaryHead & Neck

120 enrolled

EndocrineSarcoma

Neoplasm Metastasis, Neoplasms, Sarcoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine

NCT04779151 2025-12-01

NIRADO

Phase 2 Terminated

51 enrolled

Biliary Tract Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms

NCT04139902 2025-10-15

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

48 enrolled

Dermatologic

Melanoma

NCT04837209 2025-10-01

NADiR

Phase 2 Not yet recruiting

32 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07115927 2025-08-19

RODEO

40 enrolled

Endometrial Neoplasms

NCT04409002 2025-08-15

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Phase 2 Completed

18 enrolled 11 charts

Pancreatic Neoplasms

NCT04493060 2025-08-07

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Phase 2 Completed

22 enrolled 17 charts

Pancreatic Neoplasms

NCT04926324 2025-06-29

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

Phase 1/2 Terminated

3 enrolled

Phase 2 Not yet recruiting

Rectal Neoplasms

NCT07013851 2025-06-10

NADIA

25 enrolled

GynecologicOther solid neoplasm

MMRd/MSI-H Stage II-III Endometrial Cancer

NCT05239546 2025-05-25

NAIO

25 enrolled

Colonic Neoplasms

NCT03833479 2025-05-21

ATOMICC

134 enrolled

Uterine Cervical Neoplasms

NCT06385548 2025-04-01

LiDer

Phase 1/2 Withdrawn

Endometrial Neoplasms

NCT06757244 2025-03-18

DOVIPA

35 enrolled

Pancreatic Neoplasms

NCT05784012 2025-03-13

RADIAN

Phase 1/2 Recruiting

34 enrolled

GastrointestinalOther solid neoplasm

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06762405 2025-02-18

PREDIR-NEOREC

Phase 3 Recruiting

68 enrolled

Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)

NCT06365970 2025-02-03

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Phase 2 Withdrawn

GastrointestinalOther solid neoplasm

MMR-D/MSI-H Colorectal Cancers

NCT05855811 2024-07-15

PREDOSTAR

400 enrolled

Neoplasms, Recurrence, Neoplasms, Second Primary

NCT04817956 2024-02-29

IMPRESS-N

3,000 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06059495 2024-02-05

DEWI

59 enrolled

Adenocarcinoma - GEJ

NCT03016338 2024-01-30

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

51 enrolled

Endometrial Neoplasms

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04940637 2023-05-12

UNITO-001

Other solid neoplasmThoracic

70 enrolled

Lung Neoplasms, Mesothelioma

NCT03654833 2023-03-14

MiST

Other solid neoplasmThoracic

186 enrolled

Mesothelioma, Malignant

NCT05405192 2023-02-28

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

Phase 2 Withdrawn

Gestational Trophoblastic Disease

NCT04681469 2022-08-04

PRIME

49 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04895046 2022-06-29

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Phase 2 Withdrawn

Neoplasm Metastasis, Cholangiocarcinoma

NCT04679064 2021-08-27

NItCHE-MITO33

Phase 3 Unknown

427 enrolled